Repligen (NASDAQ:RGEN - Get Free Report) had its price objective cut by investment analysts at Evercore ISI from $140.00 to $130.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has an "in-line" rating on the biotechnology company's stock. Evercore ISI's price objective would indicate a potential downside of 0.71% from the stock's current price.
Several other brokerages also recently issued reports on RGEN. Wolfe Research raised shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 price objective for the company in a research report on Tuesday, April 29th. JPMorgan Chase & Co. lowered their target price on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Barclays initiated coverage on Repligen in a report on Tuesday, June 24th. They issued an "overweight" rating and a $150.00 price target on the stock. HC Wainwright reiterated a "buy" rating and set a $180.00 price objective on shares of Repligen in a report on Monday, May 5th. Finally, Canaccord Genuity Group reduced their price target on Repligen from $170.00 to $150.00 and set a "hold" rating for the company in a research report on Wednesday, April 16th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, Repligen presently has an average rating of "Moderate Buy" and an average target price of $170.75.
Read Our Latest Stock Report on Repligen
Repligen Price Performance
Shares of RGEN stock traded down $3.07 during trading hours on Tuesday, hitting $130.94. 176,805 shares of the company's stock were exchanged, compared to its average volume of 723,657. The stock's 50-day moving average is $125.88 and its 200-day moving average is $139.50. The stock has a market cap of $7.36 billion, a price-to-earnings ratio of -291.17, a price-to-earnings-growth ratio of 3.72 and a beta of 1.11. The company has a debt-to-equity ratio of 0.27, a current ratio of 6.79 and a quick ratio of 5.79. Repligen has a 52 week low of $102.97 and a 52 week high of $182.52.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.35 by $0.04. The firm had revenue of $169.17 million for the quarter, compared to analyst estimates of $163.65 million. Repligen had a positive return on equity of 4.53% and a negative net margin of 3.93%. The business's quarterly revenue was up 10.4% compared to the same quarter last year. During the same period last year, the company earned $0.28 EPS. As a group, research analysts forecast that Repligen will post 1.72 EPS for the current year.
Institutional Investors Weigh In On Repligen
Institutional investors and hedge funds have recently made changes to their positions in the business. Signaturefd LLC boosted its stake in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 124 shares in the last quarter. Sava Infond d.o.o. acquired a new position in Repligen during the 4th quarter worth approximately $29,000. Raiffeisen Bank International AG bought a new position in Repligen in the fourth quarter worth approximately $29,000. Twin Tree Management LP bought a new stake in shares of Repligen during the first quarter valued at approximately $29,000. Finally, Itau Unibanco Holding S.A. bought a new stake in shares of Repligen during the fourth quarter valued at approximately $40,000. Institutional investors own 97.64% of the company's stock.
About Repligen
(
Get Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Further Reading
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
